WHO世界卫生组织：2025年全球流感监测与应对系统扩展后呼吸道合胞病毒测序考量报告（英文版）

In recent years, rapid progress has been made in the development of new pharmaceutical interventions against respiratory syncytial virus (RSV), including monoclonal antibodies (mAbs), vaccines and antivirals. Both passive immunization and active immunization against RSV have now been recommended for infants and older adults in several countries. The ongoing surveillance of RSV viruses is thus vital for identifying the appropriateness of diagnostics and interventions.Establishing a baseline un